Distinguished in Multiple Sclerosis (MS)

Arnon Karni

6 Weizmann Street, 6423906, 
Tel Aviv, TA, IL 
Distinguished in Multiple Sclerosis (MS)
6 Weizmann Street, 6423906, 
Tel Aviv, TA, IL 
OverviewLocationsClinical Research

Overview

Arnon Karni practices in Tel Aviv, Israel. Mr. Karni is rated as a Distinguished expert by MediFind in the treatment of Multiple Sclerosis (MS). His top areas of expertise are Susac Syndrome, Multiple Sclerosis (MS), Retinal Artery Occlusion, and Myasthenia Gravis.

His clinical research consists of co-authoring 56 peer reviewed articles and participating in 1 clinical trial. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 32 articles and participated in 1 clinical trial in the study of Multiple Sclerosis (MS).

Gender
Male

Locations

6 Weizmann Street, 6423906, Tel Aviv, TA 64239, Israel

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

1 Clinical Trials

A Prospective, Multicenter, Two Arms, Open Label, Phase IIa Study to Assess the Safety and Efficacy of Once-a-month Long-acting Intramuscular Injection of 25 mg or 40mg Glatiramer Acetate (GA Depot) in Subjects With Primary Progressive Multiple Sclerosis (PPMS)
A Prospective, Multicenter, Two Arms, Open Label, Phase IIa Study to Assess the Safety and Efficacy of Once-a-month Long-acting Intramuscular Injection of 25 mg or 40mg Glatiramer Acetate (GA Depot) in Subjects With Primary Progressive Multiple Sclerosis (PPMS)
Enrollment Status: Active_not_recruiting
Publish Date: December 05, 2024
Intervention Type: Drug
Study Drug: GA Depot 
Study Phase: Phase 2

56 Total Publications

Intrathecal methotrexate in progressive multiple sclerosis: a phase 1 open-label study with long-term follow-up.
Intrathecal methotrexate in progressive multiple sclerosis: a phase 1 open-label study with long-term follow-up.
Journal: Journal of neurology
Published: February 15, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. Karni's expertise for a condition
ConditionClose
    View All 15 Experienced Conditions
    Want to save this expert for later?
    Sign Up
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile